U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease

Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says

AGIO Stock Hits Over 7-Month Highs – FDA Catalyst, ‘Seasonally Strong’ Q2 Earnings Estimate Drive Optimism

Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)

Why This Novo Nordisk Rival Just Soared To A Profit-Taking Zone

Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?

AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up

Agios Pharmaceuticals (AGIO) Is Up 13.8% After FDA Grants Priority Review To Mitapivat In Sickle Cell Disease

Is Agios Pharmaceuticals (AGIO) A Bargain After FDA Priority Review For Mitapivat?

Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week